Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (391-400 of 740) with videos related to

Pageof 74
Sort By:
Cancers|April 3, 2021
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa StudyEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, et al.
Frontiers in Endocrinology|March 11, 2022
Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical StudyStavroula A Paschou, Vangelis Karalis, Theodora Psaltopoulou, et al.
American Journal of Clinical Oncology|February 2, 2002
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyHaralabos P Kalofonos, Costas Nicolaides, Epaminondas Samantas, et al.
American Journal of Hematology|January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA studyMaría Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
American Journal of Hematology|February 1, 2024
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIAEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Leukemia & Lymphoma|July 28, 2020
Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the causeEfstathios Kastritis, Nikolaos Kanellias, Foteini Theodorakakou, et al.
Plos One|January 29, 2015
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysisJens Peter Andersen, Martin Bøgsted, Karen Dybkær, et al.
Cells|August 27, 2021
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health WorkersEvangelos Terpos, Ioannis P Trougakos, Vangelis Karalis, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2025
Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center ExperienceIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, et al.
Pageof 74

Showing results (391-400 of 740) with videos related to

Sort By:
Pageof 74
Cancers|April 3, 2021
Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa StudyEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, et al.
Frontiers in Endocrinology|March 11, 2022
Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical StudyStavroula A Paschou, Vangelis Karalis, Theodora Psaltopoulou, et al.
American Journal of Clinical Oncology|February 2, 2002
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyHaralabos P Kalofonos, Costas Nicolaides, Epaminondas Samantas, et al.
American Journal of Hematology|January 6, 2015
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA studyMaría Victoria Mateos, Paul G Richardson, Meletios A Dimopoulos, et al.
American Journal of Hematology|February 1, 2024
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIAEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Leukemia & Lymphoma|July 28, 2020
Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the causeEfstathios Kastritis, Nikolaos Kanellias, Foteini Theodorakakou, et al.
Plos One|January 29, 2015
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysisJens Peter Andersen, Martin Bøgsted, Karen Dybkær, et al.
Cells|August 27, 2021
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health WorkersEvangelos Terpos, Ioannis P Trougakos, Vangelis Karalis, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 29, 2025
Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center ExperienceIoannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Charalampos Filippatos, et al.
Pageof 74